Research and Markets: "Improved Therapies and Innovative Drug Delivery Techniques Are Anticipated to Revolutionise the Global Diabetes Market by 2015," Notes the Analyst of This Research

DUBLIN-(Business Wire)-September 28, 2009 - Research and Markets(http://www.researchandmarkets.com/research/c15b35/global_diabetes_ma) has announced the addition of Frost & Sullivan's new report "Global Diabetes Market" to their offering.

This Frost & Sullivan research service titled Global Diabetes Market provides insight into key industry challenges, market drivers and trends. Defining trends are examined along with revenue forecasts. A SWOT analysis is provided of the diabetes markets in the United States, Europe, Japan and rest of the world. In this research, Frost & Sullivan's expert analysts thoroughly examine the following diabetes markets: the US, Europe, Japan and the Rest-of-World. Insulin and insulin analogues and non-insulin anti-diabetic drugs markets are also studied in the research.

Market Overview

Emergence of Novel Drug Classes to Boost Market Growth

Increasing knowledge related to the pathology of diabetes will support the introduction of improved drugs to treat the disease. As healthcare moves towards the ideal of preventive medicine, there are a few companies conducting research on diabetes vaccines. If they succeed, the entire market landscape is bound to undergo instant change.

"Improved therapies and innovative drug delivery techniques are anticipated to revolutionise the global diabetes market by 2015," notes the analyst of this research. "As healthcare moves towards preventive medicine, the search for a cure for diabetes looks promising." The emergence of newer classes of drugs to treat diabetes and their co-morbidities is changing the diabetes market landscape. Long-acting GLP-1 analogs are likely to gain significance and almost match the importance of insulin in the near future. This trend is likely to be beneficial for Type-2 diabetics who have not responded to other oral anti-diabetic agents.

Asian Markets Offer Considerable Growth Potential

The Food and Drug Administration (FDA) has detailed stringent policies for the approval of diabetic drugs. These policies compel lengthier clinical trials, often resulting in the delayed launch of new drugs and increased drug development costs. "The not-so conducive regulatory environment, varying price controls across countries and parallel trading hinders the growth of the global diabetes market," adds the analyst. "In addition, generic competition arising due to patent expiries of major drugs is also restraining market expansion."

Despite these obstacles, the diabetes market is, and will continue to be, a lucrative segment of the healthcare industry. Numerous innovative drugs and drug-delivery devices are currently being researched. Given these are successful; the launch of such drugs and devices will further open up the market and boost revenue generation. "Asian markets, especially India and China, offer tremendous prospects for growth," concludes the analyst. "These markets have large diabetic populations and, with the number of undiagnosed diabetics increasing, lucrative untapped opportunities are emerging for pharmaceutical companies."

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research: